These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 18080428)

  • 1. [Immunoglobulin therapy of primary humoral immunologic deficiencies].
    Bordigoni P
    Rev Prat; 2007 Oct; 57(15):1691-8. PubMed ID: 18080428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Patient handout. Common variable immunodeficiency].
    Revue du Praticien
    Rev Prat; 2007 Oct; 57(15):1702. PubMed ID: 18080430
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID).
    Bayrakci B; Ersoy F; Sanal O; Kiliç S; Metin A; Tezcan I
    Turk J Pediatr; 2005; 47(3):239-46. PubMed ID: 16250308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin therapy: methods of delivery.
    Ballow M
    J Allergy Clin Immunol; 2008 Nov; 122(5):1038-9. PubMed ID: 18804269
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.
    Berger M
    J Clin Immunol; 2011 Oct; 31(5):924-6. PubMed ID: 21643892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.
    Haddad É; Barnes D; Kafal A
    Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics of immunoglobulins in primary immunodeficiency.
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common variable immune deficiency and treatment with intravenous immunoglobulin during pregnancy.
    Brinker KA; Silk HJ
    Ann Allergy Asthma Immunol; 2012 Jun; 108(6):464-5. PubMed ID: 22626605
    [No Abstract]   [Full Text] [Related]  

  • 9. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
    Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
    An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
    Hagan JB; Fasano MB; Spector S; Wasserman RL; Melamed I; Rojavin MA; Zenker O; Orange JS
    J Clin Immunol; 2010 Sep; 30(5):734-45. PubMed ID: 20454851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel aspects of hypogammaglobulinemic states: subcutaneous immunoglobulin treatment.
    Grunebaum E; Levy Y; Shoenfeld Y
    Isr Med Assoc J; 2002 Apr; 4(4):288-9. PubMed ID: 12001706
    [No Abstract]   [Full Text] [Related]  

  • 12. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously.
    Desai SH; Chouksey A; Poll J; Berger M
    J Allergy Clin Immunol; 2009 Oct; 124(4):854-6. PubMed ID: 19767071
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of patients with primary antibody deficiencies in Germany].
    Borte M; Oertelt C; Högy B
    Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Anti-Tumor Activity of Intravenous and Subcutaneous Immunoglobulin.
    Danieli MG; Gelardi C; Pedini V; Gabrielli A
    Isr Med Assoc J; 2018 Dec; 20(12):782-783. PubMed ID: 30550011
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of lichenoid drug eruption associated with subcutaneous immunoglobulin therapy.
    Beccastrini E; Emmi G; Caproni M; Antiga E; Francalanci S; Lorenzoni A; Emmi L
    Clin Immunol; 2011 May; 139(2):228-30. PubMed ID: 21402497
    [No Abstract]   [Full Text] [Related]  

  • 17. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.
    Moore ML; Quinn JM
    Ann Allergy Asthma Immunol; 2008 Aug; 101(2):114-21; quiz 122-3, 178. PubMed ID: 18727465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Personal experience with replacement therapy with intravenous gamma globulin].
    Litzman J; Lokaj J; Stikarovská D; Mayer J; Thon V; Eibl MM
    Vnitr Lek; 1995 Nov; 41(11):759-63. PubMed ID: 8553594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.
    Bonagura VR; Marchlewski R; Cox A; Rosenthal DW
    J Allergy Clin Immunol; 2008 Jul; 122(1):210-2. PubMed ID: 18602574
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
    Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
    J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.